Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

  • Richard G. Wunderink*
  • , Evangelos J. Giamarellos-Bourboulis
  • , Galia Rahav
  • , Amy J. Mathers
  • , Matteo Bassetti
  • , Jose Vazquez
  • , Oliver A. Cornely
  • , Joseph Solomkin
  • , Tanaya Bhowmick
  • , Jihad Bishara
  • , George L. Daikos
  • , Tim Felton
  • , Maria Jose Lopez Furst
  • , Eun Jeong Kwak
  • , Francesco Menichetti
  • , Ilana Oren
  • , Elizabeth L. Alexander
  • , David Griffith
  • , Olga Lomovskaya
  • , Jeffery Loutit
    • Shu Zhang, Michael N. Dudley, Keith S. Kaye
*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

399 Scopus citations

Fingerprint

Dive into the research topics of 'Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology